Podcasts about bcps

On episode 525 of The Nurse Keith Show nursing and healthcare career podcast, Keith interviews author and lactation pharmacologist Dr. Kaytlin Krutsch, PhD, PharmD, MBA, BCPS. In the course of their conversation, Keith and Dr. Krutsch discuss the history and science behind the very specialized topic of lactation pharmacology, and why it should be of great importance to all healthcare professionals. Kaytlin Krutsch, PhD, PharmD, MBA, BCPS is a lactation pharmacologist who literally wrote the book on medications in human milk with Dr. Thomas Hale, Hale's Medications and Mothers' Milk. Dr. Krutsch is both Director of the Infant Risk Center and Associate Professor at the Texas Tech University Health Sciences Center, and advises the Food and Drug Administration, the Human Milk Banking Association of Northern America, and the pharmaceutical industry on lactation pharmacology and lactation research. Dr. Krutsch believes families deserve better answers to questions about breastfeeding and medications, and designs research that addresses their questions while creating a comprehensive information cycle that empowers families. This episode of the Nurse Keith Show is brought to you in collaboration with Springer Publishing, who have been delivering award-winning healthcare education and exam prep materials focused on nursing, behavioral health, and the health sciences for more than 70 years. We thank Springer Publishing for their support. Connect with Dr. Kaytlin Krutsch and The Infant Risk Center ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠LinkedIn Instagram Facebook Infant Risk Center website Hale's Medications and Mother's Milk Contact Nurse Keith about holistic career coaching to elevate your nursing and healthcare career at ⁠⁠⁠⁠⁠⁠⁠NurseKeith.com⁠⁠⁠⁠⁠⁠⁠. Keith also offers services as a motivational and keynote speaker and freelance nurse writer. You can always find Keith on⁠⁠⁠⁠⁠⁠⁠ LinkedIn⁠⁠⁠⁠⁠⁠⁠. Are you looking for a novel way to empower your career and move forward in life? Keith's wife, Shada McKenzie, is a gifted astrologer and reader of the tarot who combines ancient and modern techniques to provide valuable insights into your motivations, aspirations, and life trajectory, and she offers listeners of The Nurse Keith Show a 10% discount on their first consultation. Contact Shada at ⁠⁠⁠⁠⁠⁠⁠TheCircelandtheDot.com ⁠⁠⁠⁠⁠⁠⁠or shada@thecircleandthedot.com.

The Future Is Now: APhA President Randy McDonough on Leading Change in Independent PharmacyWhat does the future of independent pharmacy look like—and how do we get there?In this powerful episode of Independent Insights, APhA President and Health Mart pharmacy owner Randy McDonough joins McKesson Health Mart's Chief Pharmacist Nancy Lyons for a candid conversation about the urgent changes needed in pharmacy—and the bold vision that can lead us forward.Randy shares his frontline perspective as both a national leader and a practicing owner.Whether you're a pharmacist, technician, or pharmacy owner, this episode will leave you inspired, informed, and ready to take action. Tune in and be part of the movement to redefine the role—and the value—of independent pharmacy in healthcare.HostSuzanne Feeney, PharmDSenior Director, Pharmacy SolutionsMcKesson/ Health MartGuestsRandy McDonough, PharmD, MS, BCGP, BCPS, FAPhAPresident, American Pharmacists Association (APhA) and Health Mart Pharmacy OwnerNancy Lyons, BSPharm, MBA, CDCESVice President, Chief Pharmacy OfficerMcKesson/ Health MartResourcesHealth Mart Pharmacies can access Health Mart University (HMU) for: Helpful CE courses, advanced trainings, and more Health Mart pharmacists to claim their CE credit for weekly Gamechanger episodes  The views and opinions expressed in this podcast are those of the guest and do not necessarily represent the views or positions of Health Mart, McKesson or its affiliates or subsidiaries ("McKesson”). The information provided herein is for informational purposes only and does not constitute the rendering of clinical, legal or other professional advice by McKesson.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sairah Ahmed, MD The treatment landscape for relapsed/refractory (R/R) large B-cell lymphoma has significantly shifted, with CAR T-cell therapies now offering curative potential in the second-line setting. But these advances also raise important questions, like how to identify the right candidates and navigate logistical barriers to ensure timely, equitable access. Joining Dr. Charles Turck to explore these critical considerations is Dr. Saira Ahmed, Associate Professor in the Department of Lymphoma and Myeloma and the CAR T Program Director in the Department of Lymphoma and Myeloma at the MD Anderson Cancer Center.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Hope S. Rugo, MD, FASCO Not only is PI3Kα the most common mutation seen in patients with HR+/HER2- advanced breast cancer, but it's also associated with endocrine therapy resistance and more aggressive cancer growth. Given its prevalence and impact on outcomes, it's important to know how and when to test for this mutation and how emerging targeted therapies might change our approach in clinical practice. Joining Dr. Charles Turck to share her insights on PI3Kα testing and targeted therapies for HR+/HER2- advanced breast cancer is Dr. Hope Rugo, Director of the Women's Cancers Program, Division Chief of Breast Medical Oncology and Professor of the Department of Medical Oncology and Therapeutics Research at City of Hope Comprehensive Cancer Center.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Neil M. Iyengar, MD Due to their wild-type inhibition, first-generation PIK3CA inhibitors for HR+/HER2- advanced breast cancer were limited by significant toxicities, including hyperglycemia, rash, and diarrhea. But now, mutation-specific PIK3CA inhibitors could help improve tolerability and adherence as well as simplify dosing strategies—all while maintaining efficacy. To learn more about the efficacy and safety of current and emerging PIK3CA-targeted therapies, Dr. Charles Turck speaks with Dr. Neil Iyengar, Co-Director of the Breast Oncology Program and Director of Cancer Survivorship Service at Winship Cancer Institute at Emory University.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Neil M. Iyengar, MD Guest: Komal Jhaveri, MD, FACP The second-line treatment of HR+/HER2-advanced breast cancer has evolved in recent years, particularly with the rise of biomarker-driven strategies targeting PI3Kα and other mutations. But given these advances, there's a lot we need to think about when selecting therapy, like the differences between selective and non-selective inhibitors, toxicity profiles, and shared decision-making. Joining Dr. Charles Turck to share their insights on those key considerations and how we can personalize care for patients with PI3Kα-mutated HR+/HER2- advanced breast cancer are Drs. Komal Jhaveri and Neil Iyengar. Dr. Jhaveri is the section head for the Endocrine Therapy Research Program in the Breast Medicine Service at Memorial Sloan Kettering Cancer Center, and Dr. Iyengar is the Co-Director of the Breast Oncology Program at the Winship Cancer Institute at Emory University.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Matthew Lunning, DO, FACP Despite FDA approvals and growing clinical integration, CAR T-cell therapies remain clouded by misconceptions, some of which could impact clinical decision-making and delay appropriate referrals. To help set the record straight on CAR T-cell therapy, Dr. Charles Turck speaks with Dr. Matthew Lunning about the realities of patient selection, safety, and access. Dr. Lunning is an Associate Professor in the Division of Hematology/Oncology at the University of Nebraska Medical Center.

Listen in as we explore the latest pharmacologic strategies for HIV prevention—before and after exposure. Our expert panel breaks down key considerations for PrEP and PEP, including indications, drug selection, dosing, and monitoring.Special guest(s):Caitlin Prather, PharmD, BCACP, AAHIVPClinical Pharmacy Specialist, Ambulatory CareInova Health SystemMichael A. Deaney, PharmD, AAHIVPInfectious Diseases Clinical PharmacistChildren's Hospital ColoradoYou'll also hear practical advice from TRC's Editorial Advisory Board member:Andrea Darby-Stewart, MDAssociate Director, Honor Health Family Medicine Residency ProgramClinical Professor of Family, Community & Occupational MedicineThe University of Arizona College of Medicine - PhoenixFor the purposes of disclosure, Dr. Prather reports a relevant financial relationship [HIV PrEP] with Viiv Healthcare (speakers bureau).The other speakers have nothing to disclose.  All relevant financial relationships have been mitigated.This podcast is an excerpt from one of TRC's monthly live CE webinars, the full webinar originally aired in June 2025.TRC Healthcare offers CE credit for this podcast. Log in to your Pharmacist's Letter, Pharmacy Technician's Letter,or Prescriber Insights account and look for the title of this podcast in the list of available CE courses.Claim CreditThe clinical resources mentioned during the podcast are part of a subscription to Pharmacist's Letter, Pharmacy Technician's Letter, and Prescriber Insights: Checklist: HIV Pre-Exposure Prophylaxis (PrEP)Checklist: HIV Postexposure Prophylaxis (PEP) ChecklistSend us a textIf you're not yet a subscriber, find out more about our product offerings at trchealthcare.com. Follow, rate, and review this show in your favorite podcast app. Find the show on YouTube by searching for ‘TRC Healthcare' or clicking here. You can also reach out to provide feedback or make suggestions by emailing us at ContactUs@trchealthcare.com.

Kevin Chen, PharmD, MS, BCOP, CPP, and Amanda Cass, PharmD, BCPS, BCOP, share key insights about ROS1, non-small cell lung cancer, and the new approved drug taletrectinib.

In this episode of the Society of Critical Care Medicine (SCCM) Podcast, host Marilyn N. Bulloch, PharmD, BCPS, FCCM, speaks with Christy C. Forehand, PharmD, BCCCP, FCCM, about retaining highly skilled pharmacists in the ICU setting. Dr. Forehand, a clinical pharmacy specialist and residency program director at Augusta University Medical Center and the University of Georgia College of Pharmacy, shares evidence-based insights and personal reflections on how pharmacist retention directly impacts quality and safety in patient care. The conversation highlights growing concerns around burnout and attrition among ICU pharmacists, underscoring how their involvement improves clinical and economic outcomes—ranging from medication safety and reduced ventilator days to optimized transitions of care. Drawing on American College of Clinical Pharmacy (ACCP) publications and American Society of Health-System Pharmacists (ASHP) guidance, Dr. Forehand outlines strategies for building retention plans that prioritize recognition, advancement opportunities, career mentorship, and structural supports such as protected administrative time. She emphasizes how institutional practices such as improved scheduling, remote work models, and role-specific stipends can prevent burnout while reinforcing team trust and efficiency. Resources referenced in this episode: SCCM's Leadership, Empowerment, and Development (LEAD) Program, which supports professional development Rewards, Recognition, and Advancement for Clinical Pharmacists (Bondi DS, et al. J Am Coll Clin Pharm. 2023;6:427-439)

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Whitney Trotter Ross, MD, MSCI Despite advances in endometriosis treatment, bias and stigma continue to delay diagnosis and disrupt care for many patients. Informed, empathetic care is key for supporting diverse patient populations. Dr. Charles Turck sits down with Dr. Whitney Ross to unpack how historical misconceptions still influence prescribing habits and discuss actionable strategies for counseling, selecting a treatment plan, and building trust. Dr. Ross is an Assistant Professor of Obstetrics and Gynecology in the Division of Minimally Invasive Gynecologic Surgery at Washington University in St. Louis.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Manali Kamdar, MD Although CAR T-cell therapies have transformed the treatment of B-cell malignancies, a major logistical and socioeconomic barrier remains: patients are typically required to stay near a certified treatment center for at least 4 weeks after infusion to manage potential adverse events. So to help improve patient access, a recent study explored exactly when toxicities occur and whether post-infusion monitoring could be shortened without compromising safety. And based on the findings, it's time to rethink the 4-week monitoring window. To learn more about the study's results and what they mean for patient monitoring, safety, and broader outcomes, tune in to hear Dr. Charles Turck speak with Dr. Manali Kamdar, who authored a poster on this topic that was presented at the 2025 American Society of Clinical Oncology Annual Meeting.

Discover the essential contributions of pharmacists in patient care with We're Your Pharmacist, a monthly podcast from ASHP. This episode features Mariah Hollabaugh, director of pharmacy at Citizens Memorial Hospital, Hayle Gillespie, medication access specialist at Citizens Memorial Hospital, and Jodie Gregg, an advocate and patient. Gain insights into the diverse opportunities within the pharmacy profession and learn how pharmacists are making a difference every day.  The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, joined Over the Counter to discuss the importance of insulin delivery and how advancements in this space are expected to improve diabetes outcomes.

Drug shortages continue to be a significant issue in the healthcare system, affecting various aspects of patient care and imposing substantial costs on hospitals and health systems. According to Vizient's 2024 drug shortages survey, U.S. hospitals are spending approximately 20 million hours annually managing these shortages, resulting in nearly $900 million in associated labor costs. The survey highlights that 74% of facilities reported exceeding their pharmacy budgets due to drug shortages, with pediatric facilities facing particularly significant financial and labor strain.   Kyle Hoelting, director of pharmacy supply assurance and stewardship and Nikola Markoski, director of pharmacy sourcing strategic solutions and analytics join host Katie Korte, vice president Vizient Reserve to delve into the results of Vizient's 2024 drug shortage survey.   Guest speakers:  Kyle Hoelting, Pharm.D, BCPS Director, Pharmacy Supply Assurance & Stewardship Vizient Center for Pharmacy Practice Excellence   Nikola Markoski, Pharm.D, MBA Director, Pharmacy Sourcing Strategic Solutions & Analytics Vizient   Host:  Katie Kortie, Pharm.D, MHA, BCPS, BCCCP Vice President, Strategy & Program Lead, Vizient Reserve Vizient   Show Notes: [00:47-01:14] Kyle and Niko Backgrounds [01:15-05:04] What's different about this year's survey and what made 2023 a critical year in the drug shortage landscape [05:05-08:27] How data was collected, what did the mix of information tells us and the biggest insights or patterns that surfaced in the survey [08:28-12:25] What Vizient's built or enabled that's made a difference in this space [12:26-15:55] How best to prepare for and respond to shortages from an inventory perspective   Links | Resources:  Beyond the Shortage: The Hidden Cost of Drug Supply Chain Disruptions Drug shortage stewardship: A novel solution for an old problem Vizient Key performance indicators for the management of drug shortages Vizient Essential Medications List   Subscribe Today! Apple Podcasts Amazon Podcasts Spotify Android RSS Feed

Artificial intelligence (AI) will bring many opportunities to the pharmacy profession, but it can be tempting to use AI in place of critical thinking or reliable research around drug information questions (DIQs). One must wonder, will the pharmacist be held liable if AI gets it wrong? Guest Authors: Elizabeth B. Hearn, PharmD, BCACP, CDCES; Karlyn E. Hood, PharmD, BCPS; Abigail L. Torres, PharmD Music by Good Talk

Listen in as our expert panel discusses practical considerations for starting and optimizing antidepressants for treating depression and anxiety.  You'll listen to panelists cover various aspects of antidepressant use, such as serotonin syndrome, QT prolongation, and weight gain concerns.Special guest(s):Tammie Lee Demler, BS, PharmD, MBA, BCGP, BCPP Director of Pharmacy and Residency Programs, New York State Office of Mental Health State University of New York at Buffalo School of Pharmacy and Pharmaceutical Sciences Sarah E. Grady, PharmD, BCPS, BCPPProfessor, Drake University College of Pharmacy and Health SciencesClinical Pharmacist, Inpatient Behavioral Health Unit, Broadlawns Medical CenterYou'll also hear practical advice from TRC's Editorial Advisory Board member:Craig D. Williams, PharmD, FNLA, BCPSClinical Professor of Pharmacy PracticeOregon Health and Science UniversityNone of the speakers have anything to disclose. This podcast is an excerpt from one of TRC's monthly live CE webinars, the full webinar originally aired in May 2025.TRC Healthcare offers CE credit for this podcast. Log in to your Pharmacist's Letter, Pharmacy Technician's Letter,or Prescriber Insights account and look for the title of this podcast in the list of available CE courses.Claim CreditThe clinical resources related to this podcast are part of a subscription to Pharmacist's Letter, Pharmacy Technician's Letter, and Prescriber Insights.Clinical Resources: Choosing AntidepressantsSwitching AntidepressantsCombining and Augmenting AntidepressantsPharmacotherapy of Anxiety Disorders in AdultsSend us a textIf you're not yet a subscriber, find out more about our product offerings at trchealthcare.com. Follow, rate, and review this show in your favorite podcast app. Find the show on YouTube by searching for ‘TRC Healthcare' or clicking here. You can also reach out to provide feedback or make suggestions by emailing us at ContactUs@trchealthcare.com.

Join clinical experts Cheryl Rosenfeld, DO, FACE, FACP, FSVM, ECNU, Madhuri M. Vasudevan, MD, MPH, FACE, and Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP, to learn how the AACE Patient Journey of Diabetes Technology supports people with diabetes in navigating their treatment options with confidence. This patient-friendly resource, developed from AACE clinical guidelines and reviewed by Diabetes Sisters, a leading patient advocacy organization, provides clear and accurate information on diabetes technologies, from glucose monitors to insulin delivery devices. The experts also highlight how members of the endocrine care team are using this tool to empower people with diabetes to manage their journey. This episode is brought to you with the support of Abbott, Novo Nordisk, Medtronic, and Vertex.

We all know that clinician burnout negatively impacts the quality of patient care. That's why pharmacy residency accrediting bodies now emphasize resident well-being and professional sustainability as core components of residency training earlier in clinician careers. The American Society of Health-System Pharmacists (ASHP) Accreditation Standards for PGY1 and PGY2 Pharmacy Residencies include a formal requirement for programs to address resilience, well-being, and burnout prevention, reflecting the increasing recognition of burnout in healthcare. Joining us to talk that out are Tony Huke, Senior Pharmacy Executive Director with Vizient Pharmacy Advisory Solutions and Kendra Gage, Inpatient Clinical Pharmacist and the PGY 1 Residency Program Director at UCHealth, University of Colorado Hospital in Aurora, Colorado.   Guest speakers:  Tony Huke, PharmD, BCPS, FASHP Senior Pharmacy Executive Director Vizient Pharmacy Advisory Solutions   Kendra Gage, PharmD, BCPS Inpatient Clinical Pharmacist PGY1 Pharmacy Residency Program Director UCHealth   Host:  Kerry Schwarz, PharmD, MPH  Senior Clinical Manager, Evidence-Based Medicine and Outcomes Center for Pharmacy Practice Excellence (CPPE)   Show Notes:  [01:11-03:25] What's new at the national level in terms of pharmacy resident resiliency and well-being [03:26-03:56] The intentionality of well-being in pharmacy residency programs [03:57-05:12] Examples from Kendra's program [05:13-06:40]  Program expectations to address resilience [06:41-08:33]  Assessment and potential metrics of resiliency programs [08:34-11:06]  The role of pharmacy leadership and residency program directors in resiliency [11:07-12:34] Impact of resiliency programs so far   Links | Resources: Accreditation Standards for PGY1 and PGY2 Pharmacy Residencies   Subscribe Today! Apple Podcasts Amazon Podcasts Spotify Android RSS Feed

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Matthew Lunning, DO, FACP Despite FDA approvals and growing clinical integration, CAR T-cell therapies remain clouded by misconceptions, some of which could impact clinical decision-making and delay appropriate referrals. To help set the record straight on CAR T-cell therapy, Dr. Charles Turck speaks with Dr. Matthew Lunning about the realities of patient selection, safety, and access. Dr. Lunning is an Associate Professor in the Division of Hematology/Oncology at the University of Nebraska Medical Center.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: John Koo, MD As the array of novel therapies for plaque psoriasis expands, a strategy to navigate treatment options is to focus on the specific needs of different patient groups, like Medicare-aged patients. ILUMYA® (tildrakizumab-asmn) is the only biologic for plaque psoriasis guaranteed to be covered under the medical benefit of Medicare, with no prior authorization and zero cost as a likely possibility. Join Dr Charles Turck and Dr John Koo as they share insights on the efficacy, safety, and accessibility of ILUMYA in this patient population. Dr. Koo is a Professor of Dermatology at the University of California at San Francisco School of Medicine.

Creatine is often associated with athletic performance, but growing evidence points to its broader benefits for brain health, aging, and overall muscle preservation. This episode breaks down what pharmacists need to know about creatine's evidence-based uses, safety considerations, and counseling opportunities. Tune in to strengthen your knowledge and help ensure patients receive accurate, evidence-based information about this widely used supplement.  HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTMark Smith, PharmD, CDCES, AFAA-CGFIPharmacistUAB MedicineIan Haywood,  PharmD, BCPS, CDCESClinical PharmacistBaptist Memorial HospitalPharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/CPE INFORMATION Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe the evidence-based uses of creatine beyond athletic performance, including its potential benefits for brain health and aging.2. Identify key counseling points for pharmacists when discussing creatine supplementation with patients.0.05 CEU/0.5 HrUAN: 0107-0000-25-200-H01-PInitial release date: 6/9/2025Expiration date: 6/9/2026Additional CPE details can be found here.

Creatine is often associated with athletic performance, but growing evidence points to its broader benefits for brain health, aging, and overall muscle preservation. This episode breaks down what pharmacists need to know about creatine's evidence-based uses, safety considerations, and counseling opportunities. Tune in to strengthen your knowledge and help ensure patients receive accurate, evidence-based information about this widely used supplement. HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTMark Smith, PharmD, CDCES, AFAA-CGFIPharmacistUAB MedicineIan Haywood,  PharmD, BCPS, CDCESClinical PharmacistBaptist Memorial Hospital Pharmacist Members, REDEEM YOUR CPE HERE! Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe the evidence-based uses of creatine beyond athletic performance, including its potential benefits for brain health and aging.2. Identify key counseling points for pharmacists when discussing creatine supplementation with patients.0.05 CEU/0.5 HrUAN: 0107-0000-25-200-H01-PInitial release date: 6/9/2025Expiration date: 6/9/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP In addition to heavy menstrual bleeding, patients with uterine fibroids often deal with many other considerable effects on their physical and mental wellbeing. To provide optimal care, it's important to recognize the full impact of fibroids, communicate carefully about treatment options, and promote equitable access to care. Dr. Charles Turck sits down with Dr. Ayman Al-Hendy to learn more about how we can address the multifaceted burden of uterine fibroids. Dr. Al-Hendy is a Professor of Obstetrics and Gynecology and the Director of Translational Research at the University of Chicago Pritzker School of Medicine.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Joseph E. Patruno, MD From delayed diagnosis to chronic pain and fertility issues, endometriosis presents a range of challenges that require individualized attention. By focusing on each patient's unique symptoms and priorities, we can better tailor care and improve outcomes. Join Dr. Mary Katherine Cheeley as she speaks with Dr. Joseph Patruno, an OB/GYN at Lehigh Valley Jefferson Health Network, about practical strategies for delivering comprehensive, patient-centered care.

Long COVID continues to affect millions, leaving patients with persistent symptoms that impact daily life and overall health. Pharmacists are uniquely positioned to recognize these patients, recommend supportive treatments, and provide guidance on symptom management. Tune in to learn how you can help improve the quality of life for those struggling with this complex condition. HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTDan Majerczyk, Pharm.D., Ed.M., FCCP, BCPS, BCADM, CACPAssociate Professor of Clinical Sciences/Chair of Teaching and Academic ExcellenceRoosevelt University College of Science, Health and PharmacyPharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/CPE INFORMATION Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1.  Identify common symptoms of Long COVID and the pharmacist's role in recognizing patients who may need further evaluation or support.2. Describe strategies for managing Long COVID symptoms, including pharmacologic and non-pharmacologic approaches.0.05 CEU/0.5 HrUAN: 0107-0000-25-198-H01-PInitial release date: 6/2/2025Expiration date: 6/2/2026Additional CPE details can be found here.

Long COVID continues to affect millions, leaving patients with persistent symptoms that impact daily life and overall health. Pharmacists are uniquely positioned to recognize these patients, recommend supportive treatments, and provide guidance on symptom management. Tune in to learn how you can help improve the quality of life for those struggling with this complex condition.HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTDan Majerczyk, Pharm.D., Ed.M., FCCP, BCPS, BCADM, CACPAssociate Professor of Clinical Sciences/Chair of Teaching and Academic ExcellenceRoosevelt University College of Science, Health and Pharmacy Pharmacist Members, REDEEM YOUR CPE HERE! Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Identify common symptoms of Long COVID and the pharmacist's role in recognizing patients who may need further evaluation or support.2. Describe strategies for managing Long COVID symptoms, including pharmacologic and non-pharmacologic approaches.0.05 CEU/0.5 HrUAN: 0107-0000-25-198-H01-PInitial release date: 6/2/2025Expiration date: 6/2/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Listen in as our expert panel discusses medications for the treatment of Alzheimer dementia.  They'll review the risks and benefits of cholinesterase inhibitors, memantine, and the anti-amyloid monoclonal antibodies.  And you'll hear strategies for managing behavioral and psychological symptoms of dementia.   Special guests:Tatyana Gurvich, PharmD, BCGP, APhAssociate Professor of Clinical PharmacyMann USC School of PharmacyUCI Senior Health CenterCandace Pierce, DNP, RN, CNE, COINurse Educator, Nurse Planner, and Healthcare LeaderColibri HealthcareDarlene Moyer, MD, FAAFPAssociate Director, HonorHealth Family Medicine Residency ProgramAssociate Professor of Clinical Practice – SOMME – Arizona State UniversityClinical Associate Professor – University of Arizona College of Medicine - PhoenixYou'll also hear practical advice from panelists on TRC's Editorial Advisory Board:Stephen Carek, MD, CAQSM, DipABLMClinical Associate Professor of Family MedicinePrisma Health/USC-SOMG Family Medicine Residency ProgramUSC School of Medicine GreenvilleCraig D. Williams, PharmD, FNLA, BCPSClinical Professor of Pharmacy PracticeOregon Health and Science UniversityNone of the speakers have anything to disclose. This podcast is an excerpt from one of TRC's monthly live CE webinars, the full webinar originally aired in April 2025.TRC Healthcare offers CE credit for this podcast. Log in to your Pharmacist's Letter, Pharmacy Technician's Letter,or Prescriber Insights account and look for the title of this podcast in the list of available CE courses.Claim CreditThe clinical resources mentioned during the podcast are part of a subscription to Pharmacist's Letter, Pharmacy Technician's Letter, and Prescriber Insights: FAQ - Alzheimer Dementia Pharmacotherapy Chart – Pharmacotherapy of Dementia BehaviorsChart - Drugs with Anticholinergic ActivityChart - Send us a textCheck out our NEW podcasts.Rumor vs TruthYour trusted source for facts... where we dissect the evidence behind risky rumors and reveal clinical truths.Clinical CapsulesTRC editors break down the most impactful clinical developments - giving you clear, actionable takeaways in just minutes.If you're not yet a subscriber, find out more about our product offerings at trchealthcare.com. Follow, rate, and review this show in your favorite podcast app. Find the show on YouTube by searching for ‘TRC Healthcare' or clicking here. You can also reach out to provide feedback or make suggestions by emailing us at ContactUs@trchealthcare.com.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP Despite longstanding reliance on surgery, recent advancements have reshaped our approach to uterine fibroids. However, common myths and misconceptions have limited the adoption of newer therapies, leaving many patients unaware of their available options. Join Dr. Charles Turck and Dr. Ayman Al-Hendy as they explain shifting treatment paradigms and patient education strategies in uterine fibroid care. Dr. Al-Hendy is a Professor of Obstetrics and Gynecology and the Director of Translational Research at the University of Chicago Pritzker School of Medicine.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CPE information, and to apply for credit, please visit us at PeerView.com/EJP865. CPE credit will be available until May 8, 2026.DLL3-Targeting BiTE Therapy in SCLC: A Pharmacist's Guide to Evidence and Integration In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational funding provided by Amgen.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CPE information, and to apply for credit, please visit us at PeerView.com/EJP865. CPE credit will be available until May 8, 2026.DLL3-Targeting BiTE Therapy in SCLC: A Pharmacist's Guide to Evidence and Integration In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational funding provided by Amgen.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CPE information, and to apply for credit, please visit us at PeerView.com/EJP865. CPE credit will be available until May 8, 2026.DLL3-Targeting BiTE Therapy in SCLC: A Pharmacist's Guide to Evidence and Integration In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational funding provided by Amgen.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CPE information, and to apply for credit, please visit us at PeerView.com/EJP865. CPE credit will be available until May 8, 2026.DLL3-Targeting BiTE Therapy in SCLC: A Pharmacist's Guide to Evidence and Integration In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational funding provided by Amgen.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CPE information, and to apply for credit, please visit us at PeerView.com/EJP865. CPE credit will be available until May 8, 2026.DLL3-Targeting BiTE Therapy in SCLC: A Pharmacist's Guide to Evidence and Integration In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational funding provided by Amgen.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CPE information, and to apply for credit, please visit us at PeerView.com/EJP865. CPE credit will be available until May 8, 2026.DLL3-Targeting BiTE Therapy in SCLC: A Pharmacist's Guide to Evidence and Integration In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational funding provided by Amgen.Disclosure information is available at the beginning of the video presentation.

Listen in as our expert panel discusses medications for management of opioid use disorder. They'll review strategies to optimize buprenorphine use and clarify the role of methadone and naltrexone.Special guest:Tyler J. Varisco, PharmD, PhDUniversity of Houston College of Pharmacy Assistant Professor, Department of Pharmaceutical Health Outcomes and PolicyAssistant Director, The PREMIER CenterYou'll also hear practical advice from panelists on TRC's Editorial Advisory Board:Stephen Carek, MD, CAQSM, DipABLM, Clinical Associate Professor of Family Medicine for the Prisma Health/USC School of Medicine Greenville Family Medicine Residency Program at the University of South Carolina School of Medicine, GreenvilleCraig D. Williams, PharmD, FNLA, BCPS, Clinical Professor of Pharmacy Practice at the Oregon Health and Science UniversityFor the purposes of disclosure, Dr. Varisco reports a financial relationship [cardiology, inflammatory bowel disease] with HEALIX Infusion Therapy (research consultant).The other speakers have nothing to disclose.  All relevant financial relationships have been mitigated.This podcast is an excerpt from one of TRC's monthly live CE webinars, the full webinar originally aired in March 2025.TRC Healthcare offers CE credit for this podcast. Log in to your Pharmacist's Letter, Pharmacy Technician's Letter,or Prescriber Insights account and look for the title of this podcast in the list of available CE courses.Claim CreditThe clinical resources mentioned during the podcast are part of a subscription to Pharmacist's Letter, Pharmacy Technician's Letter, and Prescriber Insights: FAQ: Management of Opioid Use DisorderChart: Treatment of Opioid WithdrawalFAQ: Treatment of Acute Pain in Opioid Use DisorderFAQ: Meds for Opioid OverdoseSend us a textIf you're not yet a subscriber, find out more about our product offerings at trchealthcare.com. Follow, rate, and review this show in your favorite podcast app. Find the show on YouTube by searching for ‘TRC Healthcare' or clicking here. You can also reach out to provide feedback or make suggestions by emailing us at ContactUs@trchealthcare.com.

Join endocrine experts Lubaina S. Presswala, DO, FACOI, FACE; Diana Isaacs, PharmD, BCPS, BC-ADM, CDCES, FADCES; and Viral N. Shah, MD, FACE, as they explore the latest in continuous glucose monitors (CGMs) and automated insulin delivery (AID) systems for managing diabetes. In this episode, they discuss the practical applications of diabetes technology, patient selection, shared decision-making, and considerations for device use in specific populations, including athletes and pregnant individuals. This conversation provides valuable insights to help clinicians navigate device options and enhance outcomes across diverse patient scenarios.

In a wide-ranging interview, Battle Creek Public Schools Superintendent Dr. Kim Carter returns to Community Matters. This time, Carter offers insight into how possible department of education restructuring at the national level could affect Battle Creek.The superintendent also updates listeners on a bond request which will not result in a tax increase, as well as a new school building set to open - and a series of listening sessions she plans with the community.Episode ResourcesMore Info: 2025 BCPS BondNorthwestern Academy of Visual and Performing ArtsABOUT COMMUNITY MATTERSFormer WBCK Morning Show host Richard Piet (2014-2017) returns to host Community Matters, an interview program focused on community leaders and newsmakers in and around Battle Creek. Community Matters is heard Saturdays, 8:00 AM Eastern on WBCK-FM (95.3) and anytime at battlecreekpodcast.com.Community Matters is sponsored by Lakeview Ford Lincoln and produced by Livemic Communications.

See all the Healthcasts at https://www.biobalancehealth.com/healthcast-blog There is a new federal rule for lab companies that requires them to report your blood tests to you as soon as they are finished, often even before your doctor has seen them.  This rule, deemed unreasonable, was established by individuals without medical expertise (politicians), who know little about interpreting lab data or the workings of doctor's offices. Sending your lab results to you before doctors can assess them is not a decision rooted in sound medical practice but rather in the notion of individual freedom. While this is important, it does not compare to having an expert interpret your results with you. The law requiring that your lab results be sent to you as soon as they are completed does not consider the fact that these results are not designed for laymen to interpret. Additionally, lab results are meant to be analyzed alongside a patient's medical history, age, gender, and medications.  The results are not tailored to report information specific to your situation, which is how a doctor would interpret them. Lab results often lack layperson-friendly explanations. This new protocol can cause anxiety, as patients may panic over results that appear abnormal, even if they are normal for their specific medical condition and treatment. Furthermore, lab companies only request your age and gender. The factors that doctors evaluate when interpreting your results are diverse and numerous, each influencing the overall interpretation. What are the considerations that doctors add to their interpretation? Menopausal status Medical conditions Healthy normal for young and healthy adults The newest recommended ranges for health Body weight Other lab values seen on the same report The problem with you getting your own lab and interpreting it as written is multifactorial: The lab is sent to you digitally with very little explanation except for reference ranges. There is no information about who you are being compared to. Other women, both men and women? Old women? Young women? Women with symptoms or women who are well without symptoms.  The reporting of the lab results to a patient directly may hide problems that need action or create fears that are unnecessary. Anxiety over your results will continue until your doctor's appointment to discuss … so you may experience unnecessary worry in many circumstances. Reference ranges make many assumptions, but labs don't input vital information about you into their computer. your age of menopause, your weight your height (or BMI) previous illnesses and your medications. if you are on hormones or testosterone   Here is a good example. The test for pituitary hormones FSH and LH. When a woman aged 45 is menopausal, and has a very high FSH and LH, the lab says it is “normal” (in the reference range), yet the woman is having severe hot flashes, night sweats, anxiety, and insomnia.  That is not healthy or “normal”. The same two tests can be used to determine if a person is menopausal. Let's say a 42-year-old woman has elevated FSH and LH, but her estradiol is very high (200-300). To the layperson, this looks like menopause, but in reality, it is the picture of ovulation, not menopause. One has to look at another test, estradiol, to determine whether she is premenopausal and ovulating or menopausal (her estradiol would be very low, and FSH and LH would be high). See the problem? Reference Ranges don't tell you what the doctor is looking for. The same two tests, FSH and LH, are used to diagnose polycystic ovaries (PCO) too.  In women without PCO, the FSH is higher than the LH, but if the LH is greater than the FSH, the diagnosis of PCO should be considered! There is no information about this interpretation in the lab report. Falling within the reference range doesn't guarantee health or absence of symptoms. If patients are to interpret their own lab results, reference ranges should reflect health in every possible scenario. FSH and LH are influenced by BCPs and menopausal HRT. Lab results should be interpreted considering the information regarding BCPs or ERT that the patient is taking. When women are on BCPs and HRT or ERT, their FSH and LH levels are suppressed to an extremely low point. If you are unaware that the patient is taking these hormones, it may appear that the diagnosis is pituitary failure affecting estrogen levels and ovulation. Only doctors can interpret this test. There should truly be a “normal” range for those undergoing hormone replacement therapy, along with a reference range that reflects overall health, rather than merely the average for your geographical area in the US or your age group. Please make an appointment with your doctor to review your lab results so you can understand how they are interpreted. If you have questions about your lab results that are concerning you, schedule a time to discuss them with your doctor. Doctors don't have the time to explain results over the phone or through email—that is what appointments are meant for. Phone calls to doctors' offices are not intended for lab result interpretation. You or your insurance will not compensate the doctor or NP for this service over the phone.   The reference ranges for many tests and medical situations are actually wrong. If you aren't trained as a doctor or Nurse practitioner who interprets metabolic lab results every day, you could get the wrong diagnosis!!! For example, when evaluating a patient for insulin resistance, the reference range was officially changed almost two decades ago. Still, the lab companies have left the normal range very high (insulin> 18). In the revised range, fasting insulin diagnoses insulin resistance if the value is > 10. The resulting outcome is that many people are not diagnosed at a time when they can be easily treated without drugs and are told that they are “normal” when they are really experiencing insulin resistance. This is misleading and just wrong! Lab values are not adjusted to your individual situation.   Many tests are adjusted for gender; however, some are specifically adjusted for women who are menstruating regarding H/H. In other words, men and women have different “normal” H/H levels in the reference range. Women who do not menstruate or who are menopausal should be compared to the same reference range as men, but that does not happen. This leads to menopausal women, who are normal, often being told they have too many red blood cells when that is not the case. Conversely, menopausal women who are truly anemic are told they are normal, which means it takes longer to diagnose their anemia from colon cancer! The H/H should have a reference range that is considered “normal” for a woman's stage in life, depending on whether she is experiencing menstrual periods or not. Many reference ranges are averages for regions of the US and vary between lab companies; therefore, they are not reliable values for comparing patients.   For instance, the Homocysteine test has a normal range that is relatively high, and each lab has different reference ranges. This test serves as a screening tool for MTHFR genetic risk related to embolic stroke and heart disease.   The suggested treatment involves methylated B vitamins; however, the interpretation on the lab printout advises taking B12 and folic acid, which, in my experience, tends to increase the number rather than decrease it. Reference ranges for nutrients, vitamins, and minerals reflect the minimum levels needed for survival, not optimal health. For example, B12 reference range levels for B12 blood levels are listed as 200-1100 pg/ml, yet I was trained to try to achieve 400 -1500 pg/ml. The lower range of the written reference range (200-400) is not healthy. The desired blood levels for vitamins are often controversial, and various medical colleges issue new recommendations on Vitamin D levels each month. Consequently, doctors must determine which level of Vitamin D to recommend for their patients. These institutions not only provide changing reference ranges but also offer differing advice on how frequently to test Vitamin D. This inconsistency arises primarily from the ongoing debate about the minimum acceptable level of Vitamin D. I have more information about your lab results next week that your doctor may not share with you. There is a lot of controversy surrounding the reference ranges on the lab sheet, and you should know the truth in case your doctor doesn't.

Osteoporosis remains a significant health concern, with new screening and treatment guidelines aiming to improve prevention and care. This episode explores updated recommendations, the latest therapeutic options, and how medications for other conditions can impact bone health. Stay informed and ready to support your patients—tune in to learn how pharmacists can make a difference. HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTErin Raney, PharmD, BCPS, BC-ADMProfessorMidwestern University College of Pharmacy, Glendale CampusPharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/CPE INFORMATION Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Explain the updated screening and treatment guidelines for osteoporosis and their implications for patient care.2. Identify medications that affect bone health strategies for pharmacists to mitigate their impact on osteoporosis risk.0.05 CEU/0.5 HrUAN: 0107-0000-25-088-H01-PInitial release date: 4/7/2025Expiration date: 4/7/2026Additional CPE details can be found here.

Osteoporosis remains a significant health concern, with new screening and treatment guidelines aiming to improve prevention and care. This episode explores updated recommendations, the latest therapeutic options, and how medications for other conditions can impact bone health. Stay informed and ready to support your patients—tune in to learn how pharmacists can make a difference.HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTErin Raney, PharmD, BCPS, BC-ADMProfessorMidwestern University College of Pharmacy, Glendale CampusPharmacist Members, REDEEM YOUR CPE HERE! Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Explain the updated screening and treatment guidelines for osteoporosis and their implications for patient care.2. Identify medications that affect bone health strategies for pharmacists to mitigate their impact on osteoporosis risk.0.05 CEU/0.5 HrUAN: 0107-0000-25-088-H01-PInitial release date: 4/7/2025Expiration date: 4/7/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, joined Over the Counter to discuss pharmacists' role in counseling patients on GLP-1s as well as the common trends, challenges, and successes she's seen among her patient population. 

Listen in as our expert panel discusses which diabetes meds have cardiovascular (CV) benefits.  We'll review the evidence and discuss the pros and cons of SGLT2 inhibitors (dapagliflozin, empagliflozin, etc) and GLP-1 agonists (dulaglutide, semaglutide, etc) in patients with or at risk for CV disease.Special Guests:Lauren G. Pamulapati, PharmD, BCACPAssociate Professor, Ambulatory CareVirginia Commonwealth University School of PharmacyClinical Pharmacist, Hayes Willis Health Center/VCU HealthChristie Schumacher, PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCPProfessor, Pharmacy PracticeDirector, PGY2 Ambulatory Care Residency ProgramMidwestern University College of Pharmacy, Downers Grove CampusClinical Pharmacist, Northwestern MedicineTRC Editorial Advisory Board Participant:Stephen Carek, MD, CAQSM, DipABLMClinical Associate Professor of Family MedicinePrisma Health/USC-SOMG Family Medicine Residency ProgramUSC School of Medicine GreenvilleFor the purposes of disclosure, Dr. Schumacher reports a relevant financial relationship [CGM for diabetes management] with Abbott (speakers bureau).The other speakers have nothing to disclose. All relevant financial relationships have been mitigated.This podcast is an excerpt from one of TRC's monthly live CE webinars, the full webinar originally aired in February 2025.TRC Healthcare offers CE credit for this podcast. Log in to your Pharmacist's Letter, Pharmacy Technician's Letter,or Prescriber Insights account and look for the title of this podcast in the list of available CE courses.Claim CreditThe clinical resources mentioned during the podcast are part of a subscription to Pharmacist's Letter, Pharmacy Technician's Letter, and Prescriber Insights: Chart: Diabetes Medications: Cardiovascular and Kidney ImpactChart: Drugs for Type 2 Diabetes Algorithm: Stepwise Treatment of Type 2 DiabetesChart: Comparison of GLP-1 AgonistsToolbox: Improving Heart Failure CareSend us a textIf you're not yet a subscriber, find out more about our product offerings at trchealthcare.com. Follow, rate, and review this show in your favorite podcast app. Find the show on YouTube by searching for ‘TRC Healthcare' or clicking here. You can also reach out to provide feedback or make suggestions by emailing us at ContactUs@trchealthcare.com.

Pharmacy Times Continuing Education (PTCE) provides industry leading pharmacy CE to retail, oncology, managed care, specialty, and health-systems pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to deliver tailored multi-specialty education. Best Practices for Management of Hyperlipidemia: A Focus on Guidelines and Patient Adherence Educational Objectives Examine best practices for optimizing medication adherence and treatment initiation in hypercholesterolemia management Explain patient education and counseling for managing hypercholesteremia Faculty: Joseph Saseen, PharmD, BCPS, BCACP, CLS Professor and Associate Dean for Clinical Affairs University of Colorado Anschutz Medical Campus Skaggs School of Pharmacy and Pharmaceutical Sciences Aurora, Colorado   Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Executive Director, Ambulatory Pharmacy Services Grady Health System Atlanta, Georgia Joseph Saseen, PharmD, BCPS, BCACP, CLS, has the following financial relationships with commercial interests to disclose: Other Support (Lipid Monitoring Committee): Amgen (VESALIUS and OCEAN(a))   Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA, has the following financial relationships with commercial interests to disclose: Grant/Research Support: Novartis Consultant: Novartis, Regeneron   Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-9999-25-069-H01-P. The activity is available for CE credit through March 31, 2026.   This activity is jointly provided by the University of Connecticut School of Pharmacy–Storrs and Pharmacy Times Continuing Education™, and is supported by an educational grant from Novartis Pharmaceuticals Corporation.   Please follow the link below to access this activity on PTCE and claim CE credit: www.pharmacytimes.org/hyperlipidemiapodcast

Hormone replacement therapy (HRT) remains a cornerstone of managing menopausal symptoms, but understanding the latest evidence is crucial for safe and effective use. This episode dives into evidence-based therapies, weighing benefits and risks and highlighting the pharmacist's role in guiding personalized care. Tune in to stay updated on the science behind HRT and its evolving role in patient care. HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTAshley Meredith, PharmD, MPH, BCACP, BCPS, CDCES, FCCPClinical ProfessorPurdue UniversityPharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/CPE INFORMATION Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe the latest evidence-based approaches to hormone replacement therapy (HRT) for managing menopausal symptoms.2. Identify key considerations for pharmacists when counseling patients on the benefits, risks, and appropriate use of HRT.0.05 CEU/0.5 HrUAN: 0107-0000-25-087-H01-PInitial release date: 3/31/2025Expiration date: 3/31/2026Additional CPE details can be found here.

Hormone replacement therapy (HRT) remains a cornerstone of managing menopausal symptoms, but understanding the latest evidence is crucial for safe and effective use. This episode dives into evidence-based therapies, weighing benefits and risks and highlighting the pharmacist's role in guiding personalized care. Tune in to stay updated on the science behind HRT and its evolving role in patient care.HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTAshley Meredith, PharmD, MPH, BCACP, BCPS, CDCES, FCCPClinical ProfessorPurdue University Pharmacist Members, REDEEM YOUR CPE HERE! Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe the latest evidence-based approaches to hormone replacement therapy (HRT) for managing menopausal symptoms.2. Identify key considerations for pharmacists when counseling patients on the benefits, risks, and appropriate use of HRT.0.05 CEU/0.5 HrUAN: 0107-0000-25-087-H01-PInitial release date: 3/31/2025Expiration date: 3/31/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Tapering antidepressants requires careful planning to minimize withdrawal symptoms and ensure patient safety. This episode provides pharmacists with a brief update on antidepressant therapies and essential education on tapering, including recognizing withdrawal risks, adjusting schedules, and counseling patients effectively. Don't miss this opportunity to stay informed and enhance your skills in supporting patients through their mental health treatment journey. HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTSara Grady, PharmD, BCPS, BCPPProfessor, Clinical PharmacistDrake UniversityBroadlawns Medical CenterPharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/CPE INFORMATION Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe the mechanisms of action of antidepressant therapies and their implications for patient care. 2. Explain best practices for tapering antidepressants, including recognizing withdrawal risks and providing effective patient counseling.0.05 CEU/0.5 HrUAN: 0107-0000-25-075-H01-PInitial release date: 3/24/2025Expiration date: 3/24/2026Additional CPE details can be found here.

Tapering antidepressants requires careful planning to minimize withdrawal symptoms and ensure patient safety. This episode provides pharmacists with a brief update on antidepressant therapies and essential education on tapering, including recognizing withdrawal risks, adjusting schedules, and counseling patients effectively. Don't miss this opportunity to stay informed and enhance your skills in supporting patients through their mental health treatment journey.HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTSara Grady, PharmD, BCPS, BCPPProfessor, Clinical PharmacistDrake UniversityBroadlawns Medical CenterPharmacist Members, REDEEM YOUR CPE HERE! Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe the mechanisms of action of antidepressant therapies and their implications for patient care. 2. Explain best practices for tapering antidepressants, including recognizing withdrawal risks and providing effective patient counseling.0.05 CEU/0.5 HrUAN: 0107-0000-25-075-H01-PInitial release date: 3/24/2025Expiration date: 3/24/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

In this episode, Sharmeen Roy, PharmD, BCPS, Chief Strategy & Science Officer at DoseMeRx, discusses the power of precision dosing technology in optimizing pharmacy operations and improving patient outcomes. Learn how validated, EHR-integrated software is enhancing clinical efficiency, reducing errors, and personalizing medication management.

The "Pharmacy 50" Awards, recognizing the 50 Most Influential Leaders in Pharmacy, have officially been announced for 2024! This prestigious honor celebrates the most inspiring, innovative, and impactful figures in pharmacy who are driving advancements in patient care, business development, and industry reform. Now in its fourth year, the Pharmacy 50 saw a record-breaking 30% increase in peer recognition, demonstrating the growing influence of pharmacists across multiple sectors, including Community Pharmacy, Long-Term Care, Specialty Pharmacy, Health System, Digital Health, and more. Voting took place between November 15 and December 20, 2024, and this year's winners include some of the most distinguished names in the industry, with returning honorees and new leaders making their mark on pharmacy's evolving landscape.   Pharmacy 50 Class of 2024 (Listed by most votes) Anthony V. Minniti, BScPharm, RPh, FACA Jay Phipps, PharmD, MBA, FACA, FACVP Dr. Nhu Truong, PharmD Jeff Harrell, PharmD Naveena Gorrepati, PharmD Jeremy Counts, PharmD Darshan Kulkarni, PharmD, Esq. Shahida Choudhry, PharmD** (4-time winner) April Nguyen, PharmD, RAC, MPH Robin Barrett, PharmD Cody R. Morcom, PharmD, BCPS, LSSGBC Ethan Melillo, PharmD, CDOE Randy McDonough, PharmD, MS, BCGP, BCPS, FAPhA Chelsea Hustad, PharmD, CSP Greg Reybold, Esq. Renee Malarbi Rayburg, BPharm Walter Oronsaye, PharmD, MS Chidimma Gold Eneyo, PharmD Jessica Beal-Stahl, PharmD Tamar K. Lawful, PharmD, APh, CNGS DeLon Canterbury, PharmD, BCGP Frank Harvey, MBA Mike Johnston, CPhT-Adv Brent Edison, PharmD Aleata Postell Courtney B. Smith, PharmD, CSP, BCMTMS Jennifer Morrison, PharmD Katrina Azer, BPharm Josh Pirestani Bil Schmidtknecht Ultan McGlone, PharmD Katarina (Kati) Forbes, PharmD Christopher Bowens, PharmD Mahmoud Zegar, PharmD Alexandra (Ally) LaStella, PharmD Kunal Vyas Jenny Bingham, PharmD Shaun Jensen Fiona Sartoretto Verna Brandi Chane, PharmD Jonathan Ogurchak, PharmD, CSP, CPHIMS Jena Quinn, PharmD Jordan Smith, PharmD, AAHIVP, CPGx Chris Antypas, PharmD Lorneka Joseph, PharmD Derek Borkowski, PharmD Sue Ojageer, PharmD, CPGx Benjamin Jolley, PharmD Anisha Patel, BPharm Jeff Malone Pharmacy 50 Awards Ceremony - January 29, 2025 The official awards ceremony will be hosted at the Pharmacy Podcast Network headquarters in Brownsville, PA. The event will feature: A networking session at 2 PM ET The Pharmacy 50 LIVE Stream at 3 PM ET, where winners will be highlighted and interviewed Industry leaders, past winners, and special guests will be in attendance to celebrate the remarkable contributions of these pharmacy professionals. The Pharmacy 50 Awards were created to recognize individuals who are pushing the boundaries of pharmacy care. From technology and advocacy to clinical services and business innovation, this year's winners represent the best of the best across the pharmacy profession. "Each year, we see more pharmacists taking charge of their profession-leading change, innovating care models, and fighting for patient access. The Pharmacy 50 recognizes these change-makers and amplifies their voices," said Todd Eury, Founder of Pharmacy Podcast Network. This year's Pharmacy 50 Awards were proudly sponsored by RxInsider and Independent Pharmacy Cooperative (IPC), whose ongoing support of the pharmacy industry continues to fuel growth and advocacy. "RXinsider is thrilled to support the Pharmacy Podcast Network's Pharmacy50 Awards, celebrating the outstanding leaders and innovators shaping pharmacy. As a company committed to advancing pharmacy through education and innovation, RXinsider is honored to join this prestigious initiative that recognizes excellence and inspires progress." stated Gregory Cianfarani RPh, CEO of RxInsider. "We're excited to celebrate the achievements of our peers and contribute to highlighting the individuals and organizations making a meaningful impact in the pharmacy community." For more details about the Pharmacy 50 Awards, visit Pharmacy50.us About Pharmacy Podcast Network (PPN) Pharmacy Podcast Network is the leading media platform dedicated to pharmacy professionals, offering thought leadership, industry insights, and expert-driven content through podcasts, webinars, and live events. Since its founding in 2009, PPN has been the voice of pharmacy, covering community pharmacy, specialty pharmacy, digital health, advocacy, business development, and more.